Pharmacological Management of Persistent Pain in Older Persons

被引:17
作者
Reisner, Lori [1 ]
机构
[1] Univ Calif San Francisco, Sch Pharm, Dept Clin Pharm, San Francisco, CA 94143 USA
关键词
Analgesics; safety; number needed to harm; number needed to treat; neuropathic pain; LIDOCAINE PATCH 5-PERCENT; PERIPHERAL NEUROPATHIC PAIN; POSTHERPETIC NEURALGIA; DOUBLE-BLIND; MEDICATED PLASTER; EFFICACY; POLYPHARMACY; CAPSAICIN; PHARMACOGENETICS; METAANALYSIS;
D O I
10.1016/j.jpain.2011.01.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Drugs without a strong evidence base and outside of recommendations are too often prescribed for older adults. Established guidelines such as Beers criteria have identified both specific medications and certain drug daises as inappropriate for older adults, primarily due to adverse effects. Age-related physiological changes in distribution, metabolism, and elimination often alter the effects of pharmacotherapies in older adults. When designing a therapeutic program, all elements contributing to the pathophysiology of painful conditions should be considered, as well as the mechanisms of action of analgesic drug classes. Both appropriate and inappropriate medications for older adults are detailed herein, as well as their contraindications and potential drug-drug or drug-disease interactions. The number needed to treat (NNT) can be useful in considering efficacy, while the safety of a pharmacotherapy is indicated by the calculated number needed to harm (NNH). The NNT is a measure describing the number of patients who require treatment for every 1 who reaches the therapeutic goal, and the NNH describes the number of participants who manifest side effects; these can further be segregated into numbers who withdraw from studies due to intolerable side effects. These parameters, along with a patient's comorbidities and concomitant medications, should be considered when :;electing an analgesic and dose regimen. In addition, practitioners should avoid prescribing multiple-drug therapies that have overlapping pharmacodynamics or that may have an adverse pharmacokinetic interaction. Perspective: The pharmacotherapeutic armamentarium for treating pain has continued to grow. Both opioids and adjuvants are important options for treating persistent pain in older adults, a population prone to individualistic differences requiring greater treatment tailoring and optimization. (C) 2011 by the American Pain Society
引用
收藏
页码:S21 / S29
页数:9
相关论文
共 56 条
  • [1] Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways
    Adams, M
    Pieniaszek, HJ
    Gammaitoni, AR
    Ahdieh, H
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (03) : 337 - 345
  • [2] Osteoarthritis: Epidemiology
    Arden, N
    Nevitt, MC
    [J]. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2006, 20 (01): : 3 - 25
  • [3] NGX-4010, a high concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study (vol 7, pg 1106, 2008)
    Backonja, M.
    Wallace, M. S.
    Blonsky, E. R.
    [J]. LANCET NEUROLOGY, 2009, 8 (01) : 31 - 31
  • [4] Polypharmacy in the Elderly Maximizing Benefit, Minimizing Harm
    Ballentine, Noel H.
    [J]. CRITICAL CARE NURSING QUARTERLY, 2008, 31 (01) : 40 - 45
  • [5] 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study
    Baron, Ralf
    Mayoral, Victor
    Leijon, Goeran
    Binder, Andreas
    Steigerwald, Ilona
    Serpell, Michael
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (07) : 1663 - 1676
  • [6] Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: Clinical and interethnic aspects
    Bertilsson, L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 82 (05) : 606 - 609
  • [7] *BIOV CORP, ULTR ER PRESCR INF
  • [8] The capsaicin receptor: a heat-activated ion channel in the pain pathway
    Caterina, MJ
    Schumacher, MA
    Tominaga, M
    Rosen, TA
    Levine, JD
    Julius, D
    [J]. NATURE, 1997, 389 (6653) : 816 - 824
  • [9] Tramadol for osteoarthritis
    Cepeda, M. S.
    Camargo, F.
    Zea, C.
    Valencia, L.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (03):
  • [10] A 1-year Safety and Efficacy Study of Duloxetine in Patients With Fibromyalgia
    Chappell, Amy S.
    Littlejohn, Geoffrey
    Kajdasz, Daniel K.
    Scheinberg, Morton
    D'Souza, Deborah N.
    Moldofsky, Harvey
    [J]. CLINICAL JOURNAL OF PAIN, 2009, 25 (05) : 365 - 375